Dacinostat (LAQ824, NVP-LAQ824) is a potent histone deacetylase (HDAC) inhibitor primarily used in cancer research; it inhibits HDAC1 with an IC50 of 9 nM and exhibits antiproliferative activity against various human tumor cell lines, including non-small cell lung cancer (H1299, IC50 = 150 nM), colon cancer (HCT116, IC50 = 10 nM), prostate cancer (DU145 and PC3, IC50 = 18 and 23 nM, respectively), and breast cancer (MDA435, IC50 = 39 nM); it induces apoptosis in human tumor cells, causes G1-S cell cycle arrest, reduces S-phase and G2-M checkpoint accumulation, enhances acetylation of histones H3 and H4, activates the p21 promoter (AC50 = 0.30 μM), suppresses self-renewal of leukemia stem cells expressing AML1/ETO or PLZF/RARα fusion proteins, impairs short-term engraftment potential of leukemic stem cells, and inhibits tumor growth in xenograft models of human colon cancer (HCT116) in nude mice at a dose of 100 mg/kg without significant cytotoxicity; additionally, it modulates chromatin structure at the IL-10 gene promoter, leading to transcriptional repression via enhanced recruitment of HDAC11 and PU.1, and reduces IL-10 production in BALB/c macrophages.